ArticleObesity surgery2026
450-nm Blue Laser-Induced Gastric Mucosal Ablation Promotes Short-Term Weight Loss and Metabolic Benefits in Rats with Obesity.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the effects and potential mechanisms of gastric mucosal ablation (GMA) using a 450-nm blue laser on weight loss and metabolic outcomes.
methodsMale Sprague-Dawley rats were fed a 45% high-fat diet (HFD) for 15 weeks to induce obesity. Rats with obesity were then randomly assigned to the GMA group (n = 26) or the sham surgery group (n = 24). The GMA group received 450-nm blue laser-induced ablation (power: 5 W), targeting approximately 70% of the gastric mucosa. Body weight and food intake were recorded weekly. At 2, 4, and 8 weeks postoperatively, eight rats per group were randomly selected for oral glucose tolerance testing and fasting serum collection for biochemical analyses, including lipid profile, blood glucose, insulin, and ghrelin. Liver and gastric tissues were collected for histological analysis, including Oil Red O staining and immunofluorescence. Moreover, hepatic transcriptomics, western blot analyses, and hepatic lipid profiling were performed.
resultsOver the 8-week postoperative period, GMA significantly reduced body weight and food intake and improved glucose and lipid metabolism in rats with obesity compared with the sham surgery group. Gastric mucosal remodeling occurred following GMA, characterized by a reduction in ghrelin-positive cells and serum ghrelin levels, along with an increase in glucagon-like peptide-1-positive cells. Hepatic transcriptomics, western blot, and hepatic lipid profiling analyses revealed that GMA was associated with a reversal of HFD-induced suppression of the peroxisome proliferator-activated receptor-α (PPARα) pathway, accompanied by enhanced fatty acid metabolism signatures and reduced hepatic lipid accumulation.
conclusions450-nm blue laser-induced GMA demonstrated short-term effects in weight loss and metabolic improvement, accompanied by changes in ghrelin levels and hepatic PPARα pathway. Further studies are warranted to elucidate the long-term effects and more intricate mechanisms.
Indexed as
Identifiers
41518492What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.